300791 Sirio Pharma
- 37.55
- -0.05-0.13%
Sirio Pharma News
Dongfang Wealth Securities released a research report on April 26 stating that it gave Xianle Health (300791.SZ) an increase in holdings rating. The main reasons for the rating include: 1) the company published its annual report for the year 23 and the qu
Dongfang Wealth Securities released a research report on April 26 stating that it gave Xianle Health (300791.SZ) an increase in holdings rating. The main reasons for the rating include: 1) the company published its annual report for the year 23 and the quarterly report for 2024; 2) multiple categories are growing simultaneously, and endogenous business is growing rapidly; 3) profitability remains stable and is expected to continue to improve in 24 years. (Mainichi Keizai Shimbun)
Xianle Health (300791) Company Review: R&D Empowers Global Business Continued Expansion
Incident: Recently, the company exchanged views on the 2023 annual business situation, the 2024 business plan, and the E-cube Bionic efficiency technology platform. E-cube bionic efficiency technology platform unveiled, with high R&D investment and long-term layout. Company E established
Xianle Health (300791): 2024Q1 revenue is in line with expectations, and the level of endogenous profit increased beyond expectations
Incident: The company released its 2023 annual report & 2024 quarterly report. It achieved revenue of 3,582 billion yuan for the full year of 2023, +42.87% year-on-year, and net profit of 281 million yuan to mother, +32.39 million yuan year-on-year
Pacific released a research report on April 23 stating that Xianle Health (300791.SZ) was given a purchase rating, and the target price was 45.05 yuan. The main reasons for the rating include: 1) high revenue growth for the full year of 2023; 2) the endog
Pacific released a research report on April 23 stating that Xianle Health (300791.SZ) was given a purchase rating, and the target price was 45.05 yuan. The main reasons for the rating include: 1) high revenue growth for the full year of 2023; 2) the endogenous net interest rate reached a record high in 2023, and the level of endogenous profit increased beyond expectations in 2024Q1; 3) it is expected that rapid growth will continue in 2024, and the equity incentive target will be successfully achieved. (Mainichi Keizai Shimbun)
Xianle Health (300791): Continued high growth in Q4+Q1, focus on BF's profit improvement
The company continued to grow at 23Q4+24Q1, and the performance was in line with expectations. The dividend ratio increased from 30% to 71% in '23, demonstrating the importance and sincerity of shareholder returns. The results of the company's organizational restructuring and sales team upgrades in the past 2 years
Xianle Health (300791): Endogenous business continues to improve, and BF gradually improves
Core view The company continues to increase its global market share through endogenous and epitaxial expansion, continuously optimize supply chain efficiency, continuously release management efficiency, improve endogenous recovery, improve endogenous profitability significantly, and BF operations improve quarterly, and it is expected that the company can collaborate globally
Guolian Securities released a research report on April 22 stating that it gave Xianle Health (300791.SZ) a purchase rating, and the target price was 44.18 yuan. The main reasons for the rating include: 1) the high increase in revenue and profit, and the m
Guolian Securities released a research report on April 22 stating that it gave Xianle Health (300791.SZ) a purchase rating, and the target price was 44.18 yuan. The main reasons for the rating include: 1) the high increase in revenue and profit, and the maturity of the three bases in China, the US, and Europe; 2) the results of cost reduction and efficiency are remarkable, and profit levels are expected to rise steadily. (Mainichi Keizai Shimbun)
Xianle Health (300791): 23 years ended successfully and continued to promote major customer development strategies
Event: The company released its 2023 annual report and 2024 quarterly report. In '23, the company achieved operating income of 3,582 million yuan, an increase of 42.87% over the previous year; achieved net profit of 281 million yuan to mother, an increase of 32.3 million yuan over the previous year
Xianle Health (300791): Long-term and short-term logical resonance valuations are expected to increase
Incident Company's 2023 revenue was 3.58 billion yuan (+42.9% YoY), net profit attributable to mother was 280 million yuan (+32.4% YoY); 2023Q4 revenue was 1.08 billion yuan (+50.1% YoY)
Xianle Health (300791): Endogenous business focuses on BF's profit improvement
Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved revenue of 3.58 billion yuan, +42.9% year over year; realized net profit of 280 million yuan, +32.4% year on year; achieved no deduction
Xianle Health (300791.SZ) released 2023 annual results, with net profit of 281 million yuan, an increase of 32.39% over the previous year
Xianle Health (300791.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 3,582 million yuan, an increase of 42.87%; net profit attributable to shareholders of listed companies was 281 million yuan, an increase of 32.39%; net profit attributable to shareholders of listed companies deducted non-recurring profit and loss of 281 million yuan, an increase of 43.01% year on year; and basic earnings per share of 1.5585 yuan/share.
Express News | Zheshang Securities: Volkswagen will maintain a gradual recovery in 2024
Express News | Xianle Health and China Credit Insurance Guangdong Branch sign a strategic cooperation agreement
Softgel Capsules Market Size, Share & Trends Analysis Report 2023-2030, Featuring Fuji Capsule, Sirio Pharma, CAPTEK Softgel, Catalent, EuroCaps, Aenova, ProCaps Laboratories and Soft Gel Technologies
Xianle Health (300791.SZ): The repurchase was completed with a cumulative cost of 398.997 million yuan to repurchase 1.285,600 shares
Gelonghui, March 19, 丨 Xianle Health (300791.SZ) announced that as of March 18, 2024, the company had repurchased 1.285,600 shares of the company's shares through a dedicated securities account, accounting for 0.71% of the company's current total share capital of 181,562,337 shares. The highest transaction price was 35.88 yuan/share, the minimum transaction price was 25.29 yuan/share, and the total transaction amount was RMB 398.997 million (excluding transaction fees). At this point, the implementation of the company's share repurchase plan has been completed.
Zheng Liqun, Deputy General Manager and Secretary of the Board of Directors of Xianle Health (300791.SZ), increased her holdings by 27,700 shares
Xianle Health (300791.SZ) announced that Zheng Liqun, the company's deputy general manager and secretary of the board of directors, will implement the plan to increase her holdings...
Express News | Xianle Health and DSM Finnmey sign a new round of global strategic cooperation agreements
Xianle Health (300791.SZ) plans to set up an industrial fund to focus on investing in China's big health sector
Xianle Health (300791.SZ) issued an announcement. The board of directors of the company agreed that the company and Shanghai Hongzhang Investment Management Co., Ltd...
Xianle Health (300791.SZ): Currently, the company's hard capsule business volume is small
Gelonghui January 5 丨 Some investors asked Xianle Health (300791.SZ) on the investor interactive platform, “Has the price of the company's raw hollow vegetable capsule shell increased? Is there a big impact on costs?” The company replied that hollow vegetable capsule shells are mainly used for hard capsule products. Currently, the company's hard capsule business volume is small, and fluctuations in the price of this raw material have very little impact on the company's costs.
Xianle Health (300791.SZ): A total cost of 30.984,400 yuan to buy back 999,200 shares
Gelonghui, January 2, 丨 Xianle Health (300791.SZ) announced that as of December 31, 2023, the company had repurchased 999,200 shares of the company's shares through a special stock repurchase account, accounting for 0.55% of the company's current total share capital of 181,562,320 shares. The highest transaction price was 35.80 yuan/share, the minimum transaction price was 25.29 yuan/share, and the total transaction amount was 30,984,400 yuan (excluding transaction fees).
Analysis
Price Target
No Data
